Get all premium features to the best stock analysis tool

Finranks

Company

About us

Contact us

[email protected]

Follow us

Instagram
Telegram
LinkedIn

All rights reserved.

Privacy Policy Terms of Conditions

Home
Markets
Screener
News
About

ILMN - Illumina, Inc. Latest News | Finranks

Home

ILMN

(ILMN)

NMS – Real Time Price. Currency in USD

117.67

-6.73 (-5.41%)

At close: Mar 27, 2026, 4:00 PM EDT

116.00

-1.67 (-1.42%)

After-hours: Mar 27, 2026, 7:53 PM EDT

Summary
News
Chart
Financial
Dividends
Forecast
Ownership
Profile

Here's Why Illumina (ILMN) is a Strong Growth Stock

Here's Why Illumina (ILMN) is a Strong Growth Stock

Whether you're a value, growth, or momentum investor, finding strong stocks becomes easier with the Zacks Style Scores, a top feature of the Zacks Premium research service.

ILMN Stock Gains Following Expanded Collaboration With Labcorp

ILMN Stock Gains Following Expanded Collaboration With Labcorp

Illumina gains after expanding Labcorp collaboration to boost NGS oncology adoption, broaden testing access, and drive growth in precision cancer care.

Illumina and Labcorp expand collaboration to broaden access to precision oncology testing

Illumina and Labcorp expand collaboration to broaden access to precision oncology testing

SAN DIEGO, March 18, 2026 /PRNewswire/ -- Illumina, Inc. (NASDAQ: ILMN) and Labcorp (NYSE: LH), a global leader of innovative and comprehensive laboratory services, today announced an expanded collaboration to advance precision oncology through innovative applications of next-generation sequencing (NGS) solutions across the healthcare ecosystem. Projects are expected to include promoting equitable access to cancer biomarker testing by bringing it closer to patients through new distributed test offerings; generating evidence to facilitate payer coverage; and developing new tests to address areas of unmet need.

Illumina advances preventive genomics through strategic consortium with Veritas Genetics

Illumina advances preventive genomics through strategic consortium with Veritas Genetics

New collaboration aims to bring population-scale whole-genome sequencing into everyday healthcare, enabling earlier risk detection and data-driven prevention SAN DIEGO, March 16, 2026 /PRNewswire/ -- Illumina, Inc. (NASDAQ: ILMN) today announced a strategic collaboration with Veritas Genetics Powered By Fuze Health to form a consortium that aims to bring preventive genomics into everyday healthcare through health insurance plans in the United States and under other global markets, setting a new standard for proactive health management. By combining clinical-grade sequencing, advanced informatics, and member-ready reporting, the collaboration supports an integrated data ecosystem to advance research, drug discovery, and clinical trial optimization.

Illumina Stock Climbs 44.8% in a Year: What's Driving the Rally?

Illumina Stock Climbs 44.8% in a Year: What's Driving the Rally?

ILMN stock surges 44.8% in a year, fueled by NovaSeq X sequencing demand, broader NGS testing adoption, multiomics expansion and improving margins.

Here's Why Illumina (ILMN) is a Strong Momentum Stock

Here's Why Illumina (ILMN) is a Strong Momentum Stock

Wondering how to pick strong, market-beating stocks for your investment portfolio? Look no further than the Zacks Style Scores.

Here's Why Illumina (ILMN) is a Strong Value Stock

Here's Why Illumina (ILMN) is a Strong Value Stock

Wondering how to pick strong, market-beating stocks for your investment portfolio? Look no further than the Zacks Style Scores.

Videos

Final Trades: Morgan Stanley, Cisco Systems, Illumina and FTAI Aviation

Final Trades: Illumina, Columbia Banking, Alibaba and JPMorgan Chase

Press releases

Illumina and Labcorp expand collaboration to broaden access to precision oncology testing

Illumina and Labcorp expand collaboration to broaden access to precision oncology testing

SAN DIEGO, March 18, 2026 /PRNewswire/ -- Illumina, Inc. (NASDAQ: ILMN) and Labcorp (NYSE: LH), a global leader of innovative and comprehensive laboratory services, today announced an expanded collaboration to advance precision oncology through innovative applications of next-generation sequencing (NGS) solutions across the healthcare ecosystem. Projects are expected to include promoting equitable access to cancer biomarker testing by bringing it closer to patients through new distributed test offerings; generating evidence to facilitate payer coverage; and developing new tests to address areas of unmet need.

Illumina advances preventive genomics through strategic consortium with Veritas Genetics

Illumina advances preventive genomics through strategic consortium with Veritas Genetics

New collaboration aims to bring population-scale whole-genome sequencing into everyday healthcare, enabling earlier risk detection and data-driven prevention SAN DIEGO, March 16, 2026 /PRNewswire/ -- Illumina, Inc. (NASDAQ: ILMN) today announced a strategic collaboration with Veritas Genetics Powered By Fuze Health to form a consortium that aims to bring preventive genomics into everyday healthcare through health insurance plans in the United States and under other global markets, setting a new standard for proactive health management. By combining clinical-grade sequencing, advanced informatics, and member-ready reporting, the collaboration supports an integrated data ecosystem to advance research, drug discovery, and clinical trial optimization.

Alliance for Genomic Discovery expands with Regeneron Genetics Center membership and new proteomics data offering

Alliance for Genomic Discovery expands with Regeneron Genetics Center membership and new proteomics data offering

Dataset grows to more than 312,000 whole genomes with longitudinal clinical data GSK is one of the first to lead a further expansion of 50,000 whole genomes paired with proteomic data SAN DIEGO, March 5, 2026 /PRNewswire/ -- Illumina, Inc. (NASDAQ: ILMN), and Nashville Biosciences, LLC (NashBio), today announced two advancements in scale and depth of the Alliance for Genomic Discovery (AGD or the Alliance). With the addition of Regeneron Genetics Center® (RGC®) as the tenth member, the Alliance can expand the core dataset to 312,000 whole genomes.

Illumina whole-genome sequencing technology to accelerate rare disease testing in Florida

Illumina whole-genome sequencing technology to accelerate rare disease testing in Florida

Increased adoption of clinical whole-genome sequencing is advancing diagnostics for rare diseases, which affect 15 million American children SAN DIEGO, Feb. 27, 2026 /PRNewswire/ -- Illumina, Inc. (NASDAQ: ILMN) today announced that Illumina Laboratory Services, Illumina's CLIA-certified laboratory, is providing clinical sequencing and interpretation services to the new Diagnostic Lab at Florida Institute for Pediatric Rare Diseases (IPRD) at Florida State University (FSU) College of Medicine, further driving innovation in diagnostics and treatments for rare diseases. "An estimated 30 million people across the country are living with a rare disease today and clinical whole-genome testing provides a transformative opportunity to end the diagnostic odyssey for patients," said Eric Green, MD, PhD, chief medical officer of Illumina.